藥明康德(02359.HK)強烈反對針對公司的誤導性指稱
藥明康德(02359.HK)公布,注意到有美國議員於年2月12日致函美國商務部、財政部和國防部,其內容有關藥明康德。公司一向歡迎監管機構對公司所在行業的監管,過去亦多次成功通過美國政府的審查。但是,強烈反對針對公司的誤導性指稱、不確實認定和未經正當程序的預判行動。
同時,就最近提交美國眾議院和美國參議院的擬議立法草案中提及藥明康德聲明,澄清「WuXi AppTec Co., Ltd.」為公司英文名稱。WuXi或者Wuxi並非公司名稱。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.